{"0690.HK": {"short_name": "UNI-BIO GROUP", "long_name": "Uni-Bio Science Group Limited", "summary": "Uni-Bio Science Group Limited, an investment holding company, engages in the research and development, manufacture, and distribution of biological and chemical pharmaceutical products to treat human diseases in the People's Republic of China. It offers prescription drugs, including Uni-E4, a recombinant rExendin-4 injection for the treatment of Type 2 diabetes; and Uni-PTH, an injection form of recombinant human parathyroid hormone for the treatment of osteoporosis in postmenopausal women. The company also provides GeneTime, a prescription biological drug for wound healing; GeneSoft, an EGF-derivative eye drop for corneal damage and post-operative healing; Pinup, a voriconazole tablet to treat severe fungal infections; and Bokangtai, a mitiglinide tablet for the treatment of Type 2 diabetes, as well as Boshutai, an oral anti-diabetic drug targeting patients with pre-diabetes condition. Uni-Bio Science Group Limited was founded in 2001 and is headquartered in Shatin, Hong Kong.", "currency": "HKD", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "HKG", "market": "hk_market", "country": "Hong Kong", "city": "Shatin"}, "1061.HK": {"short_name": "ESSEX BIO-TECH", "long_name": "Essex Bio-Technology Limited", "summary": "Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells biopharmaceutical products in the People's Republic of China. The company operates through Ophthalmic Products and Surgical Products segments. It researches and develops basic fibroblast growth factor products for the treatment of cellular proliferation, differentiation, and migration. The company offers Beifushu eye drops for various corneal defects and punctate keratopathy, recurrent punctate keratopathy in the shallow layer, dry eye, corneal operation and poor corneal healing after the operation, geographic herpes simplex keratitis, and ballous keratitis, as well as for corneal abrasion, mild, and moderate chemical burns; and Beifushu eye gels to treat corneal transplantation and eye surface reconstruction, dry eye, cataract surgery, and corneal refractive surgery, as well as to treat various keratopathy, ocular traumas, and foreign body removal. It also provides Beifuji sprays and lyophilized powder, and Beifuxin gels for use in burn and scald wounds, acute wounds, surgical incisions, chronic wounds, skin grafting, and other applications. In addition, it offers ophthalmic and surgical products from third parties; and eye health care products, including Beifu shuhui capsules to treat fundus ocular diseases, asthenopia, and visual impairments. Further, the company distributes Carisolv, a product for the treatment of root caries, deep cavities, and dental caries, as well as for removing carious dentin tissues. Essex Bio-Technology Limited has a research collaboration agreement with AC Immune SA to develop a biological therapeutic for the treatment of neurodegenerative diseases, such as Alzheimer's disease; and license agreement with Mitotech S.A. and Mitotech LLC. Essex Bio-Technology Limited was founded in 1999 and is headquartered in Central, Hong Kong.", "currency": "HKD", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "HKG", "market": "hk_market", "country": "Hong Kong", "city": "Central"}, "3681.HK": {"short_name": "SINOMAB BIO-B", "long_name": "SinoMab BioScience Limited", "summary": "SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily mAb-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a BTK inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, NHL, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China and Hong Kong. SinoMab BioScience Limited was founded in 2001 and is headquartered in Pak Shek Kok, Hong Kong.", "currency": "HKD", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "HKG", "market": "hk_market", "country": "Hong Kong", "city": "Tai Po"}, "9969.HK": {"short_name": "INNOCARE-B", "long_name": "InnoCare Pharma Limited", "summary": "InnoCare Pharma Limited, a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It is developing Orelabrutinib (ICP-022), a Bruton's tyrosine kinase that is in registrational trials for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma, and relapsed and refractory mantle cell lymphoma; in Phase II studies for patients with relapsed and refractory marginal zone lymphoma, relapsed and refractory central nervous system lymphoma, and relapsed and refractory Waldenstrom's macroglobulinemia; and in a Phase I clinical trial for follicular lymphoma patients, as well as Phase I basket trial for B-cell malignancies. The company is also developing ICP-192, a pan-inhibitor of fibroblast growth factor receptor (FGFR) that is in Phase I/IIa clinical trial to define its maximum tolerated dose and/or optimal biological dose, and pharmacokinetics/ pharmacodynamics in patients with solid tumors; and ICP-105, a FGFR4 inhibitor, which is in Phase I dose escalation trial for the treatment of advanced hepatocellular carcinoma. Its preclinical stage products include ICP-723, a pan-inhibitor of tropomyosin-related kinase family to treat patients with neurotrophic tyrosine receptor kinase fusion-positive cancers; and ICP-330, a small-molecule inhibitor of tyrosine kinase 2 for the treatment of various T-cell mediated autoimmune disorders, such as psoriasis, inflammatory bowel disease, and systemic lupus erythematosus. The company was founded in 2015 and is headquartered in Wanchai, Hong Kong.", "currency": "HKD", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "HKG", "market": "hk_market", "country": "Hong Kong", "city": "Wanchai"}, "HCM": {"short_name": "Hutchison China MediTech Limite", "long_name": "Hutchison China MediTech Limited", "summary": "Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China. It operates through Innovation Platform and Commercial Platform segments. The company provides research and development services; and develops, manufactures, distributes, and markets prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunshan and Shang Yao brands. Its clinical stage drugs include Savolitinib, an inhibitor for the treatment of non-small cell lung cancer, papillary renal cell carcinoma, colorectal cancer, gastric cancer, and prostate cancer; and Fruquintinib, an inhibitor for the treatment of colorectal cancer and solid tumors. The company is also developing Surufatinib, an inhibitor for the treatment of pancreatic neuroendocrine tumors and solid tumors; HMPL-523, an inhibitor for the treatment of indolent non-Hodgkin's lymphoma; and HMPL-689 for the treatment of indolent non-Hodgkin's lymphoma. In addition, it engages in the development of HMPL-453, an inhibitor for the potential treatment of solid tumors; HMPL-306, a molecule dual-inhibitor of isocitrate dehydrogenase 1 and 2 for the treatment of hematological malignancies, gliomas, and solid tumors; and clinical-stage EGFR inhibitors, such as Epitinib and theliatinib. Hutchison China MediTech Limited has a clinical collaboration agreement with BeiGene, Ltd. to evaluate the safety and efficacy of combining surufatinib and fruquintinib with BeiGenes anti-PD-1 antibody tislelizumab for the treatment of various solid tumor cancers. The company was incorporated in 2000 and is headquartered in Central, Hong Kong. Hutchison China MediTech Limited is a subsidiary of Hutchison Healthcare Holdings Limited.", "currency": "USD", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "NMS", "market": "us_market", "country": "Hong Kong", "city": "Central"}, "HCM.L": {"short_name": "HUTCHISON CHINA MEDITECH LIMITE", "long_name": "Hutchison China MediTech Limited", "summary": "Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapeutics and immunotherapies for oncology and immunological diseases in the People's Republic of China. It operates through Innovation Platform and Commercial Platform segments. The company provides research and development services; and develops, manufactures, distributes, and markets prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunshan and Shang Yao brands. Its clinical stage drugs include Savolitinib, an inhibitor for the treatment of non-small cell lung cancer, papillary renal cell carcinoma, colorectal cancer, gastric cancer, and prostate cancer; and Fruquintinib, an inhibitor for the treatment of colorectal cancer and solid tumors. The company is also developing Surufatinib, an inhibitor for the treatment of pancreatic neuroendocrine tumors and solid tumors; HMPL-523, an inhibitor for the treatment of indolent non-Hodgkin's lymphoma; and HMPL-689 for the treatment of indolent non-Hodgkin's lymphoma. In addition, it engages in the development of HMPL-453, an inhibitor for the potential treatment of solid tumors; HMPL-306, a molecule dual-inhibitor of isocitrate dehydrogenase 1 and 2 for the treatment of hematological malignancies, gliomas, and solid tumors; and clinical-stage EGFR inhibitors, such as Epitinib and theliatinib. Hutchison China MediTech Limited has a clinical collaboration agreement with BeiGene, Ltd. to evaluate the safety and efficacy of combining surufatinib and fruquintinib with BeiGenes anti-PD-1 antibody tislelizumab for the treatment of various solid tumor cancers. The company was incorporated in 2000 and is headquartered in Central, Hong Kong. Hutchison China MediTech Limited is a subsidiary of Hutchison Healthcare Holdings Limited.", "currency": "GBp", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "LSE", "market": "gb_market", "country": "Hong Kong", "city": "Central"}, "SBHMY": {"short_name": "SINO BIOPHARMACEUTICAL", "long_name": "Sino Biopharmaceutical Limited", "summary": "Sino Biopharmaceutical Limited, together with its subsidiaries, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. The company operates in three segments: Chinese Medicines, Investment, and Others. Its principal products include hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; oncology medicines comprising Saiweijian injections, Yinishu tablets, Shoufu tablets, Anxian capsules, and Qianping injections; cardio-cerebral medicines, including Yilunping tablets, Tuotuo tablets, and Kaina tablets; and orthopedic medicines, such as Gaisanchun capsules and Yigu injections. The company's principal products also comprise digestive system medicines that consist of Aisuping injections, Getai tablets, and Deyou granules; anti-infectious medicines that include Tiance injections, Tianjie injections, and Tianli injections; respiratory system medicines, such as Tianqingsule inhalation powder; and others comprising Debaian cataplasms. In addition, it engages in property holding activities; the retail and distribution of pharmaceutical products; optometry for optical glasses and sale of ophthalmic products; the provision of medical management consultancy services; and outpatient and surgical procedure. Further, the company manufactures, sells, and distributes health food; and develops medical technology. Sino Biopharmaceutical Limited was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.", "currency": "USD", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PNK", "market": "us_market", "country": "Hong Kong", "city": "Wan Chai"}, "SBMFF": {"short_name": "SINO BIOPHARMACEUTICAL", "long_name": "Sino Biopharmaceutical Limited", "summary": "Sino Biopharmaceutical Limited, together with its subsidiaries, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. The company operates in three segments: Chinese Medicines, Investment, and Others. Its principal products include hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; oncology medicines comprising Saiweijian injections, Yinishu tablets, Shoufu tablets, Anxian capsules, and Qianping injections; cardio-cerebral medicines, including Yilunping tablets, Tuotuo tablets, and Kaina tablets; and orthopedic medicines, such as Gaisanchun capsules and Yigu injections. The company's principal products also comprise digestive system medicines that consist of Aisuping injections, Getai tablets, and Deyou granules; anti-infectious medicines that include Tiance injections, Tianjie injections, and Tianli injections; respiratory system medicines, such as Tianqingsule inhalation powder; and others comprising Debaian cataplasms. In addition, it engages in property holding activities; the retail and distribution of pharmaceutical products; optometry for optical glasses and sale of ophthalmic products; the provision of medical management consultancy services; and outpatient and surgical procedure. Further, the company manufactures, sells, and distributes health food; and develops medical technology. Sino Biopharmaceutical Limited was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.", "currency": "USD", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "PNK", "market": "us_market", "country": "Hong Kong", "city": "Wan Chai"}, "SMZ1.F": {"short_name": "SINO BIOPH.SUBDIV.HD-,025", "long_name": "Sino Biopharmaceutical Limited", "summary": "Sino Biopharmaceutical Limited, together with its subsidiaries, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. The company operates in three segments: Chinese Medicines, Investment, and Others. Its principal products include hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; oncology medicines comprising Saiweijian injections, Yinishu tablets, Shoufu tablets, Anxian capsules, and Qianping injections; cardio-cerebral medicines, including Yilunping tablets, Tuotuo tablets, and Kaina tablets; and orthopedic medicines, such as Gaisanchun capsules and Yigu injections. The company's principal products also comprise digestive system medicines that consist of Aisuping injections, Getai tablets, and Deyou granules; anti-infectious medicines that include Tiance injections, Tianjie injections, and Tianli injections; respiratory system medicines, such as Tianqingsule inhalation powder; and others comprising Debaian cataplasms. In addition, it engages in property holding activities; the retail and distribution of pharmaceutical products; optometry for optical glasses and sale of ophthalmic products; the provision of medical management consultancy services; and outpatient and surgical procedure. Further, the company manufactures, sells, and distributes health food; and develops medical technology. Sino Biopharmaceutical Limited was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Hong Kong", "city": "Wan Chai"}, "SMZU.F": {"short_name": "SINO BIOPHARM. UNS.ADR/20", "long_name": "Sino Biopharmaceutical Limited", "summary": "Sino Biopharmaceutical Limited, together with its subsidiaries, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. The company operates in three segments: Chinese Medicines, Investment, and Others. Its principal products include hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; oncology medicines comprising Saiweijian injections, Yinishu tablets, Shoufu tablets, Anxian capsules, and Qianping injections; cardio-cerebral medicines, including Yilunping tablets, Tuotuo tablets, and Kaina tablets; and orthopedic medicines, such as Gaisanchun capsules and Yigu injections. The company's principal products also comprise digestive system medicines that consist of Aisuping injections, Getai tablets, and Deyou granules; anti-infectious medicines that include Tiance injections, Tianjie injections, and Tianli injections; respiratory system medicines, such as Tianqingsule inhalation powder; and others comprising Debaian cataplasms. In addition, it engages in property holding activities; the retail and distribution of pharmaceutical products; optometry for optical glasses and sale of ophthalmic products; the provision of medical management consultancy services; and outpatient and surgical procedure. Further, the company manufactures, sells, and distributes health food; and develops medical technology. Sino Biopharmaceutical Limited was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.", "currency": "EUR", "sector": "Healthcare", "industry": "Biotechnology", "exchange": "FRA", "market": "dr_market", "country": "Hong Kong", "city": "Wan Chai"}}